Sunday 22 December 2024

The Pharma Letter Podcast — Episode 3 — Psychedelics in medicine

Pharmaceutical
Guy Martin
18 August 2021
podcast-episode3

More on this story...

Biotechnology
New biotechs see practice-changing potential in psychedelics
11 May 2021
Pharmaceutical
Psychedelics specialist starts Phase IIa test of lead candidate
7 April 2021
Biotechnology
MindMed's LSD: first psychedelic to show significant long-lasting clinical benefit
11 May 2022
Psychedelics
Reunion Neuroscience closes $103 million Series A financing
3 May 2024


More ones to watch >


Today's issue

Neurocrine Biosciences launches Crenessity in USA
Pharmaceutical
Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Biotechnology
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Biotechnology
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Biotechnology
Regeneron advances anticoagulant antibody program
20 December 2024
Pharmaceutical
Zealand blindsided by FDA rejection of glepaglutide
20 December 2024
Biotechnology
Astellas partners with Sangamo on cutting-edge gene therapy
20 December 2024
Biotechnology
Novartis to shut MorphSys sites amid pelabresib delay
20 December 2024

Company Spotlight

Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.




More Features in Pharmaceutical

Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Zealand blindsided by FDA rejection of glepaglutide
20 December 2024
Novo Nordisk touts CagriSema success, but results miss expectations
20 December 2024
FDA approves Ionis’ Tryngolza
20 December 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze